Liraglutide
FDA status: FDA has approved products that contain liraglutide, including Saxenda, Victoza, Xultophy 100/3.6.
PubMed: 5,684 publications mention Liraglutide, 969 of them trials or reviews. Search PubMed
- Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Karakasis P et al. Metabolism: clinical and experimental, 2025. Network Meta-Analysis, Systematic Review. PMID 39719170 · DOI
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. Rubino DM et al. JAMA, 2022. Clinical Trial, Phase III, Randomized Controlled Trial. PMID 35015037 · DOI
- Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis. Souza M et al. Hepatology (Baltimore, Md.), 2025. Systematic Review, Network Meta-Analysis. PMID 39903735 · DOI
- Liraglutide for Children 6 to <12 Years of Age with Obesity - A Randomized Trial. Fox CK et al. The New England journal of medicine, 2025. Randomized Controlled Trial, Clinical Trial, Phase III. PMID 39258838 · DOI
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. Marso SP et al. The New England journal of medicine, 2016. Randomized Controlled Trial. PMID 27295427 · DOI
ClinicalTrials.gov: 515 registered studies. See all studies
- NCT03341429 Evaluation of Liraglutide 3.0mg in Patients With Poor Weight-loss and a Suboptimal Glucagon-like Peptide-1 Response (Phase 4), completed
- NCT03260881 Liraglutide Effects on Epicardial Fat Inflammatory Genes (Phase 4), completed
- NCT01715428 Liraglutide and Cardio-Metabolic Risk Markers, completed
MedlinePlus drug information ↗FDA label (DailyMed) ↗RxNorm 475968 ↗PubChem CID 16134956 ↗Wikipedia ↗





